Use este identificador para citar ou linkar para este item: http://repositorio.ufla.br/jspui/handle/1/29312
Título: Evaluation of hypoxia inducible factor targeting pharmacological drugs as antileishmanial agents
Palavras-chave: Leishmaniosis
Hypoxia inducible factor
Resveratrol
Echinomycin
Cadmium chloride (CdCl2)
Mimosine
Data do documento: Jul-2016
Editor: Hainan Medical College
Citação: DAL'BÓ-PELEGRINI, M. et al. Evaluation of hypoxia inducible factor targeting pharmacological drugs as antileishmanial agents. Asian Pacific Journal of Tropical Medicine, [S.l.], v. 9, n. 7, p. 652-657, July 2016.
Resumo: Objective: To evaluate whether hypoxia inducible factor (HIF-1α) targeting pharmacological drugs, echinomycin, resveratrol and CdCl2 which inhibit HIF-1α stimulation, and mimosine, which enhances the stability of HIF-1α present antileishmanial properties. Methods: The leishmanicidal effect of drugs was evaluated in mouse macrophages and Balb/c mouse model for cutaneous leishmaniosis. Results: Resveratrol and CdCl2 reduced the parasite load [IC50, (27.3 ± 2.25) μM and (24.8 ± 0.95) μM, respectively]. The IC50 value of echinomycin was (22.7 ± 7.36) nM and mimosine did not alter the parasite load in primary macrophages. The macrophage viability IC50 values for resveratrol, echinomycin and CdCl2 and mimosine were >40 μM, >100 nM, >200 μM and>2 000 μM, respectively. In vivo no differences between cutaneous lesions from control, resveratrol- and echinomycin-treated Balb/c mice were detected. Conclusions: Resveratrol, echinomycin and CdCl2 reduce parasite survival in vitro. The HIF-1α targeting pharmacological drugs require further study to more fully determine their anti-Leishmania potential and their role in therapeutic strategies.
URI: http://repositorio.ufla.br/jspui/handle/1/29312
Aparece nas coleções:DME - Artigos publicados em periódicos

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
ARTIGO_Evaluation of hypoxia inducible factor targeting pharmacological drugs as antileishmanial agents.pdf494,42 kBAdobe PDFVisualizar/Abrir


Este item está licenciada sob uma Licença Creative Commons Creative Commons